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Abstract
Introduction A subpopulation (CD44+/CD24-) of breast cancer
cells has been reported to have stem/progenitor cell properties.
The aim of this study was to investigate whether this
subpopulation of cancer cells has the unique ability to invade,
home, and proliferate at sites of metastasis.
Methods CD44 and CD24 expression was determined by flow
cytometry. Northern blotting was used to determine the
expression of proinvasive and 'bone and lung metastasis
signature' genes. A matrigel invasion assay and intracardiac
inoculation into nude mice were used to evaluate invasion, and
homing and proliferation at sites of metastasis, respectively.
Results Five among 13 breast cancer cell lines examined (MDA-
MB-231, MDA-MB-436, Hs578T, SUM1315, and HBL-100)
contained a higher percentage (>30%) of CD44+/CD24- cells.
Cell lines with high CD44+/CD24- cell numbers express basal/
mesenchymal or myoepithelial but not luminal markers.
Expression levels of proinvasive genes (IL-1α, IL-6, IL-8, and
urokinase plasminogen activator [UPA]) were higher in cell lines
with a significant CD44+/CD24- population than in other cell
lines. Among the CD44+/CD24--positive cell lines, MDA-MB-
231 has the unique property of expressing a broad range of
genes that favor bone and lung metastasis. Consistent with
previous studies in nude mice, cell lines with CD44+/CD24-
subpopulation were more invasive than other cell lines.
However, only a subset of CD44+/CD24--positive cell lines was
able to home and proliferate in lungs.
Conclusion Breast cancer cells with CD44+/CD24-
subpopulation express higher levels of proinvasive genes and
have highly invasive properties. However, this phenotype is not
sufficient to predict capacity for pulmonary metastasis.
Introduction
Stem cell theory proposes that cancers arise from malignant
transformation of normal stem/progenitor cells [1-4]. The
inherent properties of stem/progenitor cells may impart their
transformed counterparts with the ability to evade traditional
antitumor therapies and to establish metastasis [3-5]. Tumori-
genic stem/progenitor cells have been documented in hema-
tologic malignancies as well as in solid tumors [6-8]. Several
studies implicated a subset of human breast cancer cells as
having enhanced ability to form tumors in immunocompro-
mised mice [9,10]. This subpopulation of cells also demon-
strated a capacity for self-renewal and generation of
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heterogeneous progeny. These cells were distinguished from
their nontumorigenic counterparts by a specific cell surface
marker profile: the CD44+/CD24-/Lineage-. However, the
potential of these tumorigenic stem/progenitor cells to estab-
lish metastasis is not known.
Metastasis is a complex process that involves not only invasion
but also homing and proliferation at sites of metastasis [11].
This process requires the activity of several genes, including
the urokinase plasminogen activator (UPA)/UPA receptor sys-
tem, cytokines (IL-1, IL-6, IL-8, IL-11, tumor necrosis factor,
and transforming growth factor-β1), chemokines and their
receptors (stromal cell-derived factor-1α and CXC chemokine
receptor [CXCR]4), and matrix metalloproteinases (MMPs)
[12-14]. Recent microarray analyse s  o f  c l o n a l  v a r i a n t s  o f
MDA-MB-231 cells that home and grow at metastatic sites
such as bone and lung have revealed a distinct gene expres-
sion pattern associated with metastasis to these sites [14,15].
Bone metastasis signature genes include CXCR4, connective
tissue-derived factor (CTGF), IL-11, the metalloproteinase-dis-
integrin family member ADAMTS1 (a disintegrin and metallo-
proteinase with thrombospondin-1) and MMP1, whereas
genes of the lung metastasis signature include CXCR4,
MMP1 and cyclo-oxygenase-2. A recent study described the
role of the receptor activator of nuclear factor-κB (RANK)/
RANK ligand in metastasis of breast cancer cells to bone [16].
Recent gene expression profiling has challenged the long held
view that metastatic cells are rare and arise during later stages
of tumor progression as a result of progressive accumulation
of mutations. An alternative possibility is that most primary
tumors contain a subset of cancer cells that has a 'metastatic
phenotype' [17-19]. We investigated whether breast cancer
cells with the CD44+/CD24- phenotype possess three essen-
tial characteristics of cells with metastatic phenotype: expres-
sion of invasion/metastasis-associated genes; invasion; and
homing and proliferation at sites of metastasis. We show that
a subgroup of breast cancer cell lines with a higher percent-
age of CD44+/CD24- cells express higher levels of proinvasive
genes and invade matrigel in vitro. However, the CD44+/
CD24- phenotype is not sufficient for homing and proliferation
at sites of metastasis.
Materials and methods
Breast cancer cell lines
Except as indicated, breast cancer cell lines were obtained
from American Type Tissue Culture Collection (Manassas, VA,
USA). SUM1315 cells were obtained from Asterand (Detroit,
MI, USA) and maintained in Dulbecco's modified eagle
medium (DMEM)/F12 (CellGro, Herndon, VA, USA) contain-
ing 5% fetal calf serum (FCS), and supplemented with 10 μg/
ml insulin and 20 ng/ml epidermal growth factor. MCF-7, T47-
D, MDA-MB-231, MDA-MB-436, MDA-MB-468, SK-BR-3,
Hs578T and HBL-100 cells were grown in minimum essential
medium containing 10% FCS. ZR-75-1 and DU4475 cells
were grown in RPMI containing 10% FCS. MCF-10A cells
were grown in DMEM/F12 media containing 5% horse serum
and the following supplements: 10 μg/ml insulin, 20 ng/ml epi-
dermal growth factor, 100 ng/ml cholera euterotoxin, 0.5 μg/
ml hydrocortisone and 2 mmol/l L-glutamine. BT474 cells
were grown in RPMI containing 10% FCS, 2 mmol/l L-
glutamine, 10 mmol/l HEPES, 1 mmol/l sodium pyrophos-
phate, 4.5 g/ml glucose, 1.5 g/ml sodium carbonate, and 10
μg/ml insulin.
Flow cytometry
Cells were washed once with phosphate-buffered saline
(PBS) and then harvested with 0.05% trypsin/0.025% EDTA.
Detached cells were washed with PBS containing 1% FCS
and 1% penicillin/streptomycin (wash buffer), and resus-
pended in the wash buffer (106 cells/100 μl). Combinations of
fluorochrome-conjugated monoclonal antibodies obtained
from BD Biosciences (San Diego, CA, USA) against human
CD44 (FITC; cat. #555478) and CD24 (PE; cat. #555428)
or their respective isotype controls were added to the cell sus-
pension at concentrations recommended by the manufacturer
and incubated at 4°C in the dark for 30 to 40 min. The labeled
cells were washed in the wash buffer, then fixed in PBS con-
taining 1% paraformaldehyde, and then analyzed on a FACS-
Vantage (BD Biosciences).
Northern analysis and reverse transcriptase polymerase 
chain reaction
RNA was isolated using RNAeasy kit (Qiagen, Valencia, CA,
USA) and 5 μg RNA was subjected to Northern analysis, as
described previously [20]. RT-PCR for IL-8 was performed
using single step RT-PCR kit from Invitrogen (Carlsbad, CA,
USA) and the following primers: 5'-GTA AAC ATG ACT TCC
AAG CTG-3' and TTT TAT GAA TTC TCA GCC CTC-3'.
Animal studies
The Institutional Animal Care and Use Committee approved all
animal studies. For intracardiac injection studies, 105 cells
were suspended in 100 μl HEPES-buffered saline and slowly
injected into the left cardiac ventricle of 7-week-old female nu/
nu mice using a 27-gauge needle (7 to 12 animals per cell
type), as described previously [21]. Animals injected with
TMD-231, LMD-231, or MDA-MB-468 cells were killed when
they developed one or more of the following signs: hind limb
paralysis from suspected spine metastasis, excessive weight
loss, visible tumors, or labored breathing from lung metastasis.
Lungs and bilateral axillary contents were collected in formalin
for hematoxylin and eosin slide preparation. Animals injected
with TMD-436 cells or DU4475 cells were killed 10 weeks
after intracardiac injection. Lungs from animals injected with
MDA-MB-468 cells (two animals) were digested with colla-
genase and hyaluronidase, and cancer cells were sorted by
flow cytometry using PE-conjugated CD326 (EpCAM, #130-
091-253; Miltenyi Biotech, Auburn, CA, USA) for enriching
cancer cells. CD326-positive cells were evaluated for CD44Available online http://breast-cancer-research.com/content/8/5/R59
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and CD24 status immediately after sorting or 1 week after
sorting.
Matrigel invasion assay
The invasion assay was performed as recommended by the
manufacturer of the invasion assay kit (#ECM554; Chemicon
International, Temecula, CA, USA). Briefly, cells were serum
starved for 24 hours and 50,000 cells were placed on the top
insert with matrigel. Serum-free media or media with 10%
serum were placed in the bottom well. The number of cells that
invaded through the matrigel was calculated using fluoromet-
ric assay. For each cell line, the fluorometric reading from bot-
tom wells with the serum-free media was defined as one unit
to determine relative change in invasion in the presence of
10% serum. Each experiment contained one or two wells with-
out serum and two wells with serum for each cell line. The
experiment was repeated twice for most cell lines except for
MCF-7, which was done thrice.
Statistical analysis
Data were analyzed with GraphPad software [22] to deter-
mine P values using Fisher's exact test.
Results
Human breast cancer cell lines differ quantitatively in the 
proportion of CD44+/CD24- cells
To test the hypothesis that human breast cancer cell lines dif-
fer in the proportion of CD44+/CD24- cells, we characterized
13 breast cancer cell lines by flow cytometry for surface
expression of CD44 and CD24. In addition to parental cell
lines, derivatives of MDA-MB-231 and MDA-MB-436 cells
were analyzed. TMD-231 cells were derived from MDA-MB-
231 cells grown in the mammary fat pad of nude mice. LMD-
231 cells were derived from MDA-MB-231 cells that had
metastasized to lung from the mammary fat pad of nude mice
[23]. TMD-436 cells were derived from MDA-MB-436 cells
grown in the mammary fat pad of nude mice. A representative
flow cytometry analysis of TMD-231, TMD-436, MCF-7,
Hs578t, and BT474 cell lines showing expression patterns of
CD44 and CD24 is shown in Figure 1. Isotype control for
TMD-436 is shown, although isotype controls were con-
ducted for all cell lines investigated. In Table 1 the results of
this analysis are summarized with respect to four fractions
defined by these two markers: CD44+/CD24-, CD44-/CD24+,
CD44+/CD24+, and CD44-/CD24-. This table also shows the
tumor type and tissue source, cell of origin, and molecular
classification based on gene expression profiling or expres-
sion of markers [24-27]. According to this classification, CK19
is expressed predominantly in cell lines of luminal type
whereas CK5, CD10, and ETS1 are expressed in cell lines of
basal origin. Vimentin is expressed in cell lines of mesenchy-
mal type. MDA-MB-231 and its derived cell lines TMD-436,
Hs578T, SUM1315, and HBL-100 all possessed an
increased CD44+/CD24- subpopulation (>30%). The immor-
talized human breast epithelial cell line MCF10A also con-
tained a CD44+/CD24-  subpopulation. However, the
percentage of the CD44+/CD24- subpopulation in this cell line
varied markedly from experiment to experiment, and appears to
be dependent on the serum used for cell culture. This was not
the case with transformed cell lines. Also, note that the paren-
tal and tumor-derived variants of MDA-MB-231 and MDA-MB-
436 had similar CD44+/CD24- subpopulations.
Breast cancer cell lines with significant CD44+/CD24- 
subpopulation express higher levels of genes associated 
with invasion
To investigate the relationship between the CD44+/CD24-
phenotype and proinvasive gene expression, Northern blot
and/or RT-PCR analyses were performed. Genes in a recently
described 'bone metastasis signature' (CXCR4, IL-11, CTGF,
osteopontin, MMP-1, and ADAMTS1) and additional genes
implicated in invasion/metastasis (IL-1α, IL-6, IL-8, and UPA)
were included in this analysis [12,14,15,21]. The relationship
between the size of the CD44+/CD24- population and expres-
sion of these genes is summarized in Figure 2a. Notably, only
the MDA-MB-231 derivatives expressed all of the genes in the
bone metastasis signature, although expression of IL-11 and
CTGF was low or undetectable in the parental cell line com-
pared with TMD-231 or LMD-231 cells. Although several cell
lines expressed low levels of CXCR4, MDA-MB-231 and its
derivatives exhibited the highest expression. This result was
independently confirmed by flow cytometry. TMD-231 and
LMD-231 cells expressed higher levels of CXCR4 (50% to
70%) than did any other cell line (data not shown). Twenty-five
per cent of DU4475 cells expressed CXCR4. Of MCF-7 cells
5% to 8% expressed CXCR4 only when maintained in phenol-
red free-charcoal dextran treated media, whereas the rest of
the cell lines did not exhibit cell surface CXCR4. MMP-1
expression was highest in Hs578T cells and the MDA-MB-
231 line and its derivatives. All other estrogen receptor (ER)-
α-negative but not ER-α-positive breast cancer cell lines
expressed lower but detectable levels of MMP-1. All cell lines
expressed similar levels of osteopontin, suggesting that its
expression is not linked to the CD44+/CD24- phenotype.
Expression of additional proinvasive genes tested was
observed predominantly in cell lines with an increased CD44+/
CD24- subpopulation. For example, expression of IL-1α, IL-6,
and IL-8 was restricted to the cell lines MDA-MB-231, TMD-
231, LMD-231, MDA-MB-436, TMD-436, Hs578T, and HBL-
100; however, sensitive RT-PCR assay revealed IL-8 expres-
sion in several cell lines at variable levels (Figure 2a). Interest-
ingly, tumor-derived or metastasis-derived variants of MDA-
MB-231 cells demonstrated enhanced expression of these
genes as compared with parental cells; this finding suggests
that cells expressing these genes at higher levels have
enhanced tumorigenic potential. Although present in cell lines
lacking CD44+/CD24- subpopulation, UPA expression was
highest in cell lines with a higher fraction of the CD44+/CD24-
subpopulation. Consistent with microarray analysis of primaryBreast Cancer Research    Vol 8 No 5    Sheridan et al.
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breast cancers, overall expression of proinvasive genes was
higher in ER-α-negative cell lines than in ER-α-positive cell
lines [28,29].
We then examined whether CD44+/CD24- and non-CD44+/
CD24- subpopulations of cells from a single cell line exhibit dif-
ferential expression of proinvasive genes. Repeated attempts
to culture CD44-/CD24- subpopulation from TMD-231, which
represents under 15% of cells, were not successful because
of poor plating efficiency. Therefore, we isolated CD44+/
CD24- and CD44+/CD24+ cells from TMD-436 cells by flow
cytometry (Figure 2b) and analyzed proinvasive gene expres-
sion either immediately by RT-PCR (data not shown) or after
culturing for a week by Northern analysis (Figure 2c). CD44+/
Figure 1
Identification of a CD44+/CD24- subpopulation in breast cancer cell lines by flow cytometry Identification of a CD44+/CD24- subpopulation in breast cancer cell lines by flow cytometry. Cells in R1 correspond to CD44+/CD24- cells. An iso-
type control corresponding to TMD-436 cells is shown.Available online http://breast-cancer-research.com/content/8/5/R59
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CD24- and CD44+/CD24+ cells exhibited a modest difference
in IL-8 but not MMP-1, IL-6, and UPA expression (Figure 2c).
These results suggest that CD44+/CD24+ cells retain expres-
sion of the proinvasive genes that we tested.
Invasive property is restricted to breast cancer cell lines 
with CD44+/CD24- subpopulation
Because only cell lines with a substantial fraction of CD44+/
CD24- cells consistently expressed proinvasive genes, we
compared the invasive capacity of cell lines with or without
CD44+/CD24- cells. We excluded the SUM1315 line from
this assay because these cells require serum and epidermal
growth factor for survival, and cannot be maintained in serum-
free media for 24 hours. Whereas breast cancer cell lines with-
out CD44+/CD24- cells lacked invasive capacity, those with
CD44+/CD24- subpopulation (MDA-MB-231, MDA-MB-436,
and Hs578T) exhibited invasion (Figure 3a). There was trend
toward increased invasion by TMD-231 and TMD-436 cells
compared with the respective parental cells (MDA-MB-231
and MDA-MB-436), although differences were not statistically
significant. These results show that the CD44+/CD24- pheno-
type of breast cancer cells is associated with invasive capac-
ity.
We also examined the invasive capacity of the CD44+/CD24-
and CD44+/CD24+ subpopulations of TMD-436 cells. Inter-
estingly, CD44+/CD24- cells were more invasive than were
CD44+/CD24+ cells (Figure 3b). These results further support
the association between CD44+/CD24- phenotype and inva-
sion.
The CD44+/CD24- phenotype is not sufficient to establish 
pulmonary metastasis
To test the hypothesis that CD44+/CD24- phenotype is suffi-
cient for the establishment of metastasis in vivo, we tested the
ability of these cell lines to establish pulmonary metastasis
after intracardiac injection. In addition to the requirement of
invasive property, metastatic cells should have the following
properties: survival in circulation, adherence to target organ,
extravasation, and initiation of growth at the metastatic site. Int-
racardiac injection of cancer cells into nude mice allows
assessment of the metastatic capacity of cancer cells subse-
quent to entry into circulation [14,15,21,30-33]. Nude mice
injected with cells were monitored for visible symptoms of
metastasis for up to 10 weeks. The metastasis pattern of each
of the cell lines tested is summarized in Table 2. TMD-231
injected animals exhibited signs of metastasis as early as 6
weeks, with most animals affected by 10 weeks. Metastatic
growth was detected in vertebrae, limbs, chest wall, sternum,
jaw, and scapula. Histologic staining further revealed meta-
static growths in lungs (Figure 4a). Bone and visceral organ
metastasis was further confirmed by dual energy X-ray absorp-
tiometry scans and high-resolution Faxitron images (Figure 4b)
and necropsy. Note that animals injected with either parental
MDA-MB-231 or LMD-231 cells exhibited a similar pattern of
metastasis (data not shown). Although without bone metasta-
sis, animals injected with MDA-MB-468 cells had severe mor-
bidity and mortality. In contrast, animals injected with parental
MDA-MB-436, TMD-436, Hs578T, SUM1315, or DU4475
cells did not show any symptoms of metastasis even 10 weeks
after intracardiac injection. A representative Faxitron image of
Table 1
Progenitor cell properties (CD44+/CD24-) of various breast cancer cell lines
Cell line CD44+/CD24- CD44+/CD24+ CD44-/CD24+ CD44-/CD24- Tumor typea [24,50-52] Tissue sourceb 
[24,50-52]
Cell type 
classification 
[25-27]
MDA-MB-231, TMD-231 85 ± 5 2 0 13 ± 5 AC Pleural effusion Mesenchymal
TMD-436 72 ± 5 27 ± 5 0 7 AC Pleural effusion Myoepithelial
Hs578T 86 ± 5 10 ± 5 0 2 ± 2 CS Primary Mesenchymal
SUM1315 97 ± 3 0 0 3 ± 3 IDAC Metastatic nodule Basal
HBL-100 37 ± 5 8 2 52 ± 6 Immortal Milk Myoepithelial
MDA-MB-468 3 ± 1 90 ± 6 7 ± 3 0 IAC Pleural effusion Basal
MCF-7 0 8 ± 3 87 ± 2 6 ± 2 IDAC Pleural effusion Luminal
T47-D 0 0 63 ± 3 37 ± 2 IDAC Pleural effusion Luminal
ZR-75-1 0 0 64 ± 1 36 ± 1 IDAC Ascites Luminal
BT-474 0 0 78 ± 7 22 ± 7 IDC Primary Luminal/ErbB2+
SK-BR-3 0 0 84 ± 1 16 ± 1 AC Pleural effusion Luminal/ErbB2+
DU4475 0 0 6 ± 1 94 ± 1 IDC Cutaneous nodule ND
MCF-10Aa 17 ± 4 5 ± 3 20 ± 10 58 ± 20 Immortal Fibrocyst Basal
aPercentage of MCF10A cell progenitor and other subpopulation was influenced by species and batch of serum in culture media. AC, 
adenocarcinoma; CS, carcinosarcoma; IDAC, infiltrating ductal adenocarcinoma; IAC, Invasive adenocarcinoma; IDC, Invasive ductal carcinoma; 
ND, not determined.Breast Cancer Research    Vol 8 No 5    Sheridan et al.
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Figure 2
Proinvasive and 'bone metastasis signature' gene expression patterns in cell lines with variable CD44+/CD24- subpopulation Proinvasive and 'bone metastasis signature' gene expression patterns in cell lines with variable CD44+/CD24- subpopulation. (a) A representative 
Northern analysis of bone metastasis signature genes and proinvasive genes is shown. CD44+/CD24- status and ER-α expression pattern in cell 
lines are indicated. RT-PCR results of IL-8 and the control 36B4 are shown on the right. (b) CD44 and CD24 expression patterns in CD44+/CD24- 
and CD44+/CD24+ subpopulations of TMD-436 sorted by flow cytometry. Expression in pre-sorted and post-sorted cells is shown. (c) Expression of 
IL-8, IL-6, MMP-1, and UPA in CD44+/CD24- and CD44+/CD24+ subpopulations of TMD-436 cells, as determined by Northern blot analysis. ER, 
estrogen receptor; MMP, matrix metalloproteinase; UPA, urokinase plasminogen activator.Available online http://breast-cancer-research.com/content/8/5/R59
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an animal injected with TMD-436 cells is shown in Figure 4b.
Lungs of animals injected with MDA-MB-468 or TMD-436 (6/
8), but not Hs578T, SUM1315, or DU4475 cells, showed
extensive growth of cancer cells (Table 2 and Figure 4a). Thus,
the CD44+/CD24- phenotype, while associated with invasion,
is not sufficient for establishment of metastasis.
Pulmonary metastasis of MDA-MB-468 cells is 
independent of expression of 'lung metastasis signature' 
genes
CD44+/CD24-/Lin- cells from primary breast cancers progress
to CD44+/CD24+, CD44-/CD24+, and CD44-/CD24- pheno-
types when implanted into mammary fat pad of nonobese dia-
betic/severe combined immunodeficiency mice [9]. However,
whether CD44+/CD24- cells similarly progress to a heteroge-
neous population at sites of metastasis is not known. This pos-
sibility was explored using MDA-MB-231 (with 85% CD44+/
Figure 3
Cell lines with CD44+/CD24- subpopulation are highly invasive Cell lines with CD44+/CD24- subpopulation are highly invasive. (a) Matrigel invasion properties of breast cancer cell lines with or without CD44+/
CD24- subpopulation. Number of cells invaded through matrigel to serum-free media for each cell line was set as one unit and relative invasion to 
media containing 10% fetal calf serum is shown. Mean and standard error of the mean is shown. Although invasion by TMD-231 and TMD-436 cells 
were higher than that of MDA-MB-231 and MDA-MB-436 cells, respectively, differences were not statistically significant. (b) Matrigel invasive prop-
erties of CD44+/CD24- and CD44+/CD24+ subpopulations of TMD-436 cells. P = 0.006.Breast Cancer Research    Vol 8 No 5    Sheridan et al.
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CD24- subpopulation) and MDA-MB-468 cells (with <3%
CD44+/CD24- subpopulation). Cancer cells that metastasized
to lungs were sorted and identified using CD326 antibody,
which recognizes only human epithelial cells. CD44 and
CD24 expression status in parental and lung metastasized
cells (LMD-231 and LMD-468) were analyzed by flow cytom-
etry. The CD44 and CD24 expression profiles of LMD-468
and LMD-231 cells were similar to those of the parental cells
(Figure 5a and data not shown). Thus, at sites of metastasis,
cancer cell phenotype based on CD44 and CD24 expression
does not change significantly compared with that of parental
cancer cells. Also, it is unlikely that few CD44+/CD24- cells of
MDA-MB-468 cells contributed to lung metastasis and then
progressed to become CD44+/CD24+.
We then examined whether LMD-468 cells express higher lev-
els of lung metastasis signature genes than do parental cells.
Lung metastasis signature genes were defined using clonal
variants of MDA-MB-231 cells that grew in lungs after intrac-
ardiac injection [30]. All previously described lung metastasis
signature genes that we tested were expressed in LMD-231
cells. In contrast, most of these genes were not expressed in
both MDA-MB-468 and LMD-468 cells (Figure 5b). Also,
TMD-436 cells, which grow in lungs, did not express the
majority of the lung metastasis signature genes. These results
suggest that the lung metastasis signature gene expression is
not absolutely required for lung metastasis of breast cancer
cells.
Discussion
CD44+/CD24- phenotype of breast cancer cells is 
associated with invasive properties
We investigated the importance of the stem/progenitor phe-
notype defined by CD44 positivity and CD24 negativity for
breast cancer cells to invade and metastasize. Metastasis is a
complex process that involves integrated activity of genes,
which function in discrete steps that include the following:
angiogenesis, invasion, intravasation, survival in circulation,
extravasation, and homing and proliferation at sites of metas-
tasis [19,34]. These genes include UPA/UPA receptor,
MMPs, cytokines such as IL-1, IL-6, IL-8 and IL-11, parathyroid
hormone-related peptide and the chemokine receptor CXCR4
[12,14,21,31]. Here we show that several of these genes are
expressed in cell lines that contain significant numbers of
CD44+/CD24- cells and that the expression pattern of these
genes and the CD44+/CD24- phenotype correlates with inva-
sive behavior of cell lines. However, the CD44+/CD24- pheno-
type is not sufficient for homing and growth at sites of
metastasis. Thus, steps in the cascade of events required for
the spread of cancer are dependent on distinct groups of
genes, and the CD44+/CD24-  phenotype may define the
expression of the group of genes involved in invasion.
CD44 and CD24 have been shown to regulate invasion and
metastasis of breast cancer cells either positively or nega-
tively. Although most studies have shown CD44-mediated
invasion of breast cancer cells [35,36], Lopez and coworkers
[37] showed inhibition of breast cancer metastasis by this mol-
ecule. Similarly, CD24 has been shown to promote [38] or
inhibit [39] invasion and metastasis of breast cancer cells.
However, association of CD44+/CD24- phenotype with inva-
sion observed in this study is not linked to the function of these
genes because MDA-MB-468 cells expressing both CD44
and CD24 failed to invade. Also, the CD44+/CD24- subpopu-
lation of TMD-436 was more invasive than the CD44+/CD24+
subpopulation of the same cell line (Figure 3b). Thus, the inva-
sive property is intrinsic to cells of CD44+/CD24- phenotype.
Which among the genes expressed in CD44+/CD24- cells
confers the invasive phenotype is yet to be determined
because CD44+/CD24- and CD44+/CD24+ subpopulations
of TMD-436 cells exhibited modest differences in expression
levels of the proinvasive genes tested but exhibited differ-
ences in invasion. In the original study on tumorigenic breast
cancer progenitor cells [9] CD10 and CD140b were used as
lineage markers, and so cancer cells expressing CD10 or
CD140b were excluded from progenitor cells. However, sev-
eral breast cancer cell lines that we examined express CD10
and it is considered a basal cell marker [25]. Studies are
underway to determine whether the CD44+/CD24- subpopu-
lation can be further subdivided based on the expression of
markers such as CD10 and whether such subsets have
unique invasion/metastasis properties.
Table 2
Metastasis pattern of breast cancer cell lines injected into nude mice via intracardiac route
Cell line Bone metastasis Gross lung metastasis Histologic lung metastasis
TMD-231 10/15 0/15 4/4
TMD-436 0/15 4/15 10/15
MDA-MB-468 0/10 5/10 8/8
SUM1315 0/11 0/11 0/11
Hs578T 0/10 0/10 0/10
DU4475 0/8 0/8 0/8Available online http://breast-cancer-research.com/content/8/5/R59
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The invasive metastasis properties of several of the cell lines
that we used in this study were examined by others before the
identification of CD44+/CD24- cells, and most of these stud-
ies correlated invasive properties with ER-α status and/or
expression status of mesenchymal markers such as vimentin
or MMPs [24,40,41]. These studies established a general
Figure 4
Lung metastatic properties of cell lines with or without CD44+/CD24- subpopulation Lung metastatic properties of cell lines with or without CD44+/CD24- subpopulation. (a) Hematoxylin and eosin staining of lungs in animals injected 
with TMD-231, TMD-436, MDA-MB-468, and DU4475 cells. Metastasis was not observed with DU4475. (b) Faxitron images of calcified tumor 
growth in animals injected with TMD-231 but not with TMD-436 cells (left and center). Dual energy X-ray absorptiometry whole-body scan of an ani-
mal injected with TMD-231 cells is shown on right.Breast Cancer Research    Vol 8 No 5    Sheridan et al.
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Figure 5
CD44 and CD24 status and lung metastasis signature gene expression in MDA-MB-468 and LMD-468 cells CD44 and CD24 status and lung metastasis signature gene expression in MDA-MB-468 and LMD-468 cells. (a) Flow cytometry showing CD44 
and CD24 expression in MDA-MB-468 and LMD-468 cells. (b) Expression of select lung metastasis signature genes was determined by Northern 
blot analysis. COX, cyclo-oxygenase; CXCR, CXC chemokine receptor; MMP, matrix metalloproteinase; UPA, urokinase plasminogen activator.Available online http://breast-cancer-research.com/content/8/5/R59
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trend toward increased invasiveness of ER-α-negative breast
cancer cells. However, not all ER-α-negative cells were inva-
sive (MDA-MB-468 and SK-BR-3 cells, for example) [24,42].
Our study clearly shows a direct association between the
CD44+/CD24- phenotype and invasion. However, neither our
study nor previous studies revealed an association between
homing and proliferation at sites of metastasis and ER-α sta-
tus, mesenchymal marker expression, or CD44+/CD24- phe-
notype. For example, the ER-α-positive and vimentin-negative
cell line MCF-7 lacking CD44+/CD24- subpopulation forms
osteosclerotic bone lesions on intracardiac injection in nude
mice [32]. Similarly, we observed lung metastasis of MDA-MB-
468 cells, which are ER-α negative and vimentin negative, and
lack a CD44+/CD24- subpopulation. In contrast, the vimentin-
positive and ER-α-negative cell line Hs578T, which has an
86% CD44+/CD24- subpopulation, failed to form lung metas-
tasis. The minor difference in our results and previously pub-
lished data with respect to hematogenous metastasis of
Hs578T on mammary fat pad injection [24] is probably due to
low frequency of metastasis (10%). Also, we did not observe
metastasis of SUM1315 cells, with a 97% CD44+/CD24- sub-
population, in nude mice, although previous studies have
shown bone metastasis of these cells in nonobese diabetic/
severe combined immunodeficiency mice with humanized but
not mouse bone [43].
In a complementary study, Abraham and coworkers [44]
reported that the prevalence of CD44+/CD24- cells (tumors
with >10% of CD44+/CD24- cancer cells) in 22% of tumor
samples. The prevalence of these cells correlated with distant
metastasis but no other clinical parameters. Our data suggest
that the CD44+/CD24- population plays a critical role in the
invasive step of metastasis. Thus, distant metastasis in
patients with elevated levels of CD44+/CD24- cells may be
related to enhanced invasiveness of cancer cells. It is possible
that the establishment of growth at sites of metastasis is con-
trolled by a distinct set of genes whose expression is unrelated
to the CD44+/CD24- phenotype. An emerging opinion is that
reduced expression of genes involved in cell-cell communica-
tion initiates invasion, whereas re-expression of genes involved
in cell-cell communication is essential for survival and reattach-
ment of metastases [45]. Therefore, metastatic growth may be
primarily determined by signaling pathways that control the re-
expression of cell-cell communication genes, which may be
further influenced by the organ-specific microenvironment. In
this regard, the transforming growth factor-β-activated signal-
ing pathway is suggested to play a significant role in growth of
cancer cells at sites of metastasis [13,14]. Although previous
studies have identified lung metastasis signature genes using
MDA-MB-231 cells as a model system [30], our studies reveal
that the same set of lung metastasis signature genes is not
involved in metastasis of MDA-MB-468 cells. Thus, additional
studies are required to elucidate the mechanisms of tumor cell
growth at sites of metastasis.
CD44+/CD24- phenotype may define breast cancers of 
basal/myoepithelial origin
Molecular profiling studies have classified breast cancers to
five types with distinct prognostic significance: luminal type A,
luminal type B, ErbB2-positive, normal-like, and basal type
[28,29]. Patients with luminal type A tumors have the most
favorable prognosis, whereas patients with basal-type tumors
have worst prognosis. Breast cancer cell lines have also been
classified into five groups – luminal, basal, mesenchymal,
ErbB2-positive, and myoepithelial – based on gene expression
profiling [25,27]. As per gene expression profiling, basal and
mesenchymal cells are similar except for differential expres-
sion of 227 genes. Interestingly, all cell lines that contained
CD44+/CD24- population are in the basal/mesenchymal or
the myoepithelial group (Table 1). Thus, stem/progenitor cells
for luminal and ErbB2-positive breast cancers, which repre-
sent the majority of breast cancers, remain to be identified. In
this regard, a 'side population' of cells with high drug efflux
capacity has been described as cancer stem cells for breast
cancer, lung cancer, and glioblastoma [46,47]. These side
population cells have been identified in breast cancer cell lines
of luminal type, and these cells overexpress transporter genes
ABCG2 (ATP-binding cassette, subfamily G, member 2) and
ABCA3 (ATP-binding cassette, subfamily A, member 3) [46].
Cells that express higher levels of CD24 in mouse are defined
as luminal epithelial cells, and Lin-CD29hiCD24+ cells have
been defined as mammary stem cells in mouse [48,49]. Note
that all luminal cell types contain disproportionately higher lev-
els of CD44-/CD24+ cells (Table 1), and this population may
contain cancer progenitor cells corresponding to luminal type
of tumors. Identification of cancer stem cells specific for lumi-
nal cells, which represent about 70% of breast cancers, may
allow improved understanding of signaling events that are
involved in discrete steps of breast cancer progression,
including metastasis.
Conclusion
In this report we show the relationship between CD44+/
CD24- phenotype of breast cancer cells and discrete steps of
the metastatic cascade. CD44+/CD24- phenotype is associ-
ated with enhanced invasive properties and elevated expres-
sion of genes involved in invasion. One surprising finding is the
lack of correlation between CD44+/CD24- phenotype and
ability to home and proliferate at sites of metastasis. Further-
more, our studies suggest that stem/progenitor cells defined
by CD44 and CD24 identify tumorigenic progenitor cells cor-
responding to basal type.
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